These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 10766581)

  • 1. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.
    El-Sadr WM; Burman WJ; Grant LB; Matts JP; Hafner R; Crane L; Zeh D; Gallagher B; Mannheimer SB; Martinez A; Gordin F
    N Engl J Med; 2000 Apr; 342(15):1085-92. PubMed ID: 10766581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
    Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
    Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.
    Havlir DV; Dubé MP; Sattler FR; Forthal DN; Kemper CA; Dunne MW; Parenti DM; Lavelle JP; White AC; Witt MD; Bozzette SA; McCutchan JA
    N Engl J Med; 1996 Aug; 335(6):392-8. PubMed ID: 8676932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome.
    Pierce M; Crampton S; Henry D; Heifets L; LaMarca A; Montecalvo M; Wormser GP; Jablonowski H; Jemsek J; Cynamon M; Yangco BG; Notario G; Craft JC
    N Engl J Med; 1996 Aug; 335(6):384-91. PubMed ID: 8663871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.
    Aberg JA; Wong MK; Flamm R; Notario GF; Jacobson MA
    HIV Clin Trials; 2001; 2(6):453-9. PubMed ID: 11742432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.
    Oldfield EC; Fessel WJ; Dunne MW; Dickinson G; Wallace MR; Byrne W; Chung R; Wagner KF; Paparello SF; Craig DB; Melcher G; Zajdowicz M; Williams RF; Kelly JW; Zelasky M; Heifets LB; Berman JD
    Clin Infect Dis; 1998 Mar; 26(3):611-9. PubMed ID: 9524832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.
    Nightingale SD; Cameron DW; Gordin FM; Sullam PM; Cohn DL; Chaisson RE; Eron LJ; Sparti PD; Bihari B; Kaufman DL
    N Engl J Med; 1993 Sep; 329(12):828-33. PubMed ID: 8179648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
    Phillips P; Chan K; Hogg R; Bessuille E; Black W; Talbot J; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2002 Feb; 34(3):371-8. PubMed ID: 11774085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.
    Sendi PP; Craig BA; Meier G; Pfluger D; Gafni A; Opravil M; Battegay M; Bucher HC
    J Antimicrob Chemother; 1999 Dec; 44(6):811-7. PubMed ID: 10590283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
    Yangco BG; Buchacz K; Baker R; Palella FJ; Armon C; Brooks JT;
    AIDS Patient Care STDS; 2014 Jun; 28(6):280-3. PubMed ID: 24833016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.
    Lederman HM; Williams PL; Wu JW; Evans TG; Cohn SE; McCutchan JA; Koletar SL; Hafner R; Connick E; Valentine FT; McElrath MJ; Roberts NJ; Currier JS;
    J Infect Dis; 2003 Dec; 188(12):1794-803. PubMed ID: 14673757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
    Bayoumi AM; Redelmeier DA
    AIDS; 1998 Aug; 12(12):1503-12. PubMed ID: 9727572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis.
    Jung Y; Song KH; Choe PG; Park WB; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Oh MD
    Int J STD AIDS; 2017 Dec; 28(14):1426-1432. PubMed ID: 28592210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
    Kinloch-De Loës S; Hirschel BJ; Hoen B; Cooper DA; Tindall B; Carr A; Saurat JH; Clumeck N; Lazzarin A; Mathiesen L
    N Engl J Med; 1995 Aug; 333(7):408-13. PubMed ID: 7616989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.